Table 3.

Current clinical trials of anti-PD-1 combined with other therapy in R/M CC.

Combined Therapies	Name	Drug	Anti-PD-1	Phase	Size	Clinical identifier	Ref.
Targeted therapy	TKI	Lenvatinib	Pembrolizumab	II	35	NCT04865887	–
		Axitinib	Sasanlimab	I	161	NCT04458259	–
		Apatinib	Camrelizumab	II	49	NCT03816553	(15)
		Famitinib		III	172	NCT04974944	–
		Anlotinib	Sintilimab	II	42	–	(32)
		Sitravatinib	Tislelizumab	II	57	NCT05614453	–
	HDACi	Chidamide	Toripalimab	I/II	40	NCT04651127	–
		Vorinostat	Pembrolizumab	II	112	NCT04357873	–
	PAPRi	Olaparib	Pembrolizumab	II	48	NCT04483544	–
	ADC	Tisotumab vedotin	Pembrolizumab	I/II	214	NCT03786081	–
Immunotherapy	Anti-CTLA-4	Zalifrelimab	Balstilimab	I/II	154	NCT03495882	(14)
	TIL	LN-145	Pembrolizumab	II	189	NCT03108495	–
	Vaccine	GX-188E	Pembrolizumab	II	60	NCT03444376	(33)
		ISA101b	Cemiplimab	II	105	NCT04646005	–
		HPV vaccine	Sintilimab	II	20	NCT04096911	–
Chemotherapy	Platinum-based chemotherapy +/- bevacizumab		*Pembrolizumab	III	617	NCT03635567	(11)
			*Serplulimab	II	48	NCT05444374	–
			*Prolgolimab	III	136	NCT03912415	–
			Prolgolimab	II	49	NCT03912402	–
			Tislelizumab	II	49	NCT05247619	–
	Platinum-based chemotherapy + bevacizumab		*Toripalimab	II	35	NCT04973904	–
			Pembrolizumab	II	40	NCT03367871	–
	Albumin-bound paclitaxel		Serplulimab	II	143	NCT04150575	(31)
			Camrelizumab	II	122	NCT05290935	–
	TC/TP		QL1604	II/III	458	NCT04864782	–

*Represents that this combination therapy regimen was the first-line treatment for R/M CC patients.